← Leaderboards
Dipankar Ray
University Of Michigan At Ann Arbor
$2,223,890
Attributed
$3,479,344
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $422.8K · FY2011–21$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,479,344 · 2
By mechanism
R01$3,479,344 · 2
Top collaborators
- David George Beer5 shared
- Derek John Nancarrow3 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Daniel Dimaio$34,640,869
- David George Beer$7,871,560
- Erle S Robertson$33,256,575
- Dean E. Brenner$31,108,993
- Juanita L Merchant$22,602,061
Others in their field
Top investigators on “Mutate”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutateUbiquitin LigasePlayAffectReportingTumorDown-RegulationMediatingMolecularMutationProtein DegradationProteinsResistanceResponseCell DeathCohortBaseMalignant NeoplasmsCellsMessenger RnaMutantNovel TherapeuticsEpithelialCbl Gene
Grant awards (10)
RNF128 Regulation of TP53 in Barrett's Progression$422,751
R01 · FY2021 · CA · contact PI
RNF128 Regulation of TP53 in Barrett's Progression$422,751
R01 · FY2020 · CA · contact PI
RNF128 Regulation of TP53 in Barrett's Progression$410,069
R01 · FY2019 · CA · contact PI
RNF128 Regulation of TP53 in Barrett's Progression$422,751
R01 · FY2018 · CA
RNF128 Regulation of TP53 in Barrett's Progression$414,063
R01 · FY2017 · CA
Targeting SMURF2 as a novel therapy for EGFR driven tumors$282,478
R01 · FY2015 · CA · contact PI
Targeting SMURF2 as a novel therapy for EGFR driven tumors$274,002
R01 · FY2014 · CA · contact PI
Targeting SMURF2 as a novel therapy for EGFR driven tumors$265,529
R01 · FY2013 · CA · contact PI
Targeting SMURF2 as a novel therapy for EGFR driven tumors$282,475
R01 · FY2012 · CA · contact PI
Targeting SMURF2 as a novel therapy for EGFR driven tumors$282,475
R01 · FY2011 · CA · contact PI